As reported by the company, it increased its turnover by 65% in 2018 at the end of the year with revenues of 11,8 million euros.
The company’s EBITDA reached 2 million euros during the previous year, which represents a growth of 844% over 2017.
The founders and executive directors of the company, Sergi Audivert and Miguel Angel Bonachera, believe that the good performance of the 2018 results is the consequence of the international expansion plan and the launch of new products in recent years.
The company operates in 66 countries with 135 product references and has another 100 launches planned in the next 18 months, which is expected to maintain a “high rate of revenue growth in the coming years.”
Check all AB-BIOTICS financial information here.